Purpose: The immuno-modulatory activity of DNA hypomethylating agents (DHA) suggests they may improve the effectiveness of cancer immunotherapies. The phase 1b NIBIT-M4 trial tested this hypothesis using the next-generation DHA guadecitabine combined with ipilimumab. Experimental Design: Unresectable Stage III/IV melanoma patients received escalating doses of guadecitabine 30, 45 or 60 mg/m2/day subcutaneously on Days 1-5 every 3 weeks, and ipilimumab 3 mg/kg intravenously on Day 1 every 3 weeks, starting 1 week after guadecitabine, for 4 cycles. Primary endpoints were safety, tolerability and maximum tolerated dose of treatment; secondary were immune-related (ir) disease control rate (DCR) and objective response rate (ORR); exploratory were changes in methylome, transcriptome, and immune contextures in sequential tumor biopsies, and pharmacokinetics. Results: Nineteen patients were treated; 84% had grade 3/4 adverse events, neither dose limiting toxicities per protocol nor overlapping toxicities were observed. Ir-DCR and ir-ORR were 42% and 26%, respectively. Median CpG site methylation of tumor samples (n=8) at Week 4 (74.5%) and Week 12 (75.5%) was significantly (p<0.05) lower than at baseline (80.3%), with a median of 2454 (Week 4) and 4131 (Week 12) differentially expressed genes. Among the 136 pathways significantly (p<0.05; Z score >2 or <-2) modulated by treatment, the most frequently activated were immune-related. Tumor immune contexture analysis (n=11) demonstrated up-regulation of HLA class I on melanoma cells, an increase in CD8+, PD-1+ T cells and in CD20+ B cells in post-treatment tumor cores. Conclusions: Treatment of guadecitabine combined with ipilimumab is safe and tolerable in advanced melanoma, and has promising immunomodulatory and anti-tumour activity. Copyright ©2019, American Association for Cancer Research.
Di Giacomo, A.M., Covre, A., Finotello, F., Rieder, D., Danielli, R., Sigalotti, L., et al. (2019). Guadecitabine plus ipilimumab in unresectable melanoma: the NIBIT-M4 clinical trial. CLINICAL CANCER RESEARCH, 25(24), 7351-7362 [10.1158/1078-0432.CCR-19-1335].
Guadecitabine plus ipilimumab in unresectable melanoma: the NIBIT-M4 clinical trial
Di Giacomo, Anna Maria;Covre, Alessia;Danielli, Riccardo;Cutaia, Ornella;Fazio, Carolina;Monterisi, Santa;Miracco, Clelia;Maio, Michele
2019-01-01
Abstract
Purpose: The immuno-modulatory activity of DNA hypomethylating agents (DHA) suggests they may improve the effectiveness of cancer immunotherapies. The phase 1b NIBIT-M4 trial tested this hypothesis using the next-generation DHA guadecitabine combined with ipilimumab. Experimental Design: Unresectable Stage III/IV melanoma patients received escalating doses of guadecitabine 30, 45 or 60 mg/m2/day subcutaneously on Days 1-5 every 3 weeks, and ipilimumab 3 mg/kg intravenously on Day 1 every 3 weeks, starting 1 week after guadecitabine, for 4 cycles. Primary endpoints were safety, tolerability and maximum tolerated dose of treatment; secondary were immune-related (ir) disease control rate (DCR) and objective response rate (ORR); exploratory were changes in methylome, transcriptome, and immune contextures in sequential tumor biopsies, and pharmacokinetics. Results: Nineteen patients were treated; 84% had grade 3/4 adverse events, neither dose limiting toxicities per protocol nor overlapping toxicities were observed. Ir-DCR and ir-ORR were 42% and 26%, respectively. Median CpG site methylation of tumor samples (n=8) at Week 4 (74.5%) and Week 12 (75.5%) was significantly (p<0.05) lower than at baseline (80.3%), with a median of 2454 (Week 4) and 4131 (Week 12) differentially expressed genes. Among the 136 pathways significantly (p<0.05; Z score >2 or <-2) modulated by treatment, the most frequently activated were immune-related. Tumor immune contexture analysis (n=11) demonstrated up-regulation of HLA class I on melanoma cells, an increase in CD8+, PD-1+ T cells and in CD20+ B cells in post-treatment tumor cores. Conclusions: Treatment of guadecitabine combined with ipilimumab is safe and tolerable in advanced melanoma, and has promising immunomodulatory and anti-tumour activity. Copyright ©2019, American Association for Cancer Research.File | Dimensione | Formato | |
---|---|---|---|
Guadecitabine-plus-ipilimumab-auth-manuscr-2019.pdf
non disponibili
Descrizione: Author manuscript
Tipologia:
Post-print
Licenza:
NON PUBBLICO - Accesso privato/ristretto
Dimensione
4.4 MB
Formato
Adobe PDF
|
4.4 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Guadecitabine-plus-ipilimumab-DiGiacomo-2019.pdf
non disponibili
Descrizione: Free full-text sul sito dell'editore
Tipologia:
PDF editoriale
Licenza:
NON PUBBLICO - Accesso privato/ristretto
Dimensione
1.29 MB
Formato
Adobe PDF
|
1.29 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
https://hdl.handle.net/11365/1083690